DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0135335 A1 Collier Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20070135335A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0135335 A1 Collier et al. (43) Pub. Date: Jun. 14, 2007 (54) THERAPEUTIC MOLECULES Related U.S. Application Data (75) Inventors: Greg Collier, Victoria (AU); Ken (60) Provisional application No. 60/446,191, filed on Feb. Walder, Victoria (AU); Lyndal 10, 2003. Kerr-Bayles, Victoria (AU) Publication Classification Correspondence Address: SCULLY, SCOTT, MURPHY & PRESSER, P.C. (51) Int. Cl. 4OO GARDEN CITY PLAZA A6II 38/17 (2006.01) SUTE 3OO A6IR 48/00 (2006.01) GARDEN CITY, NY 11530 (US) C07K I4/705 (2006.01) (52) U.S. Cl. ............................... 514/12: 514/44; 530/350 (73) Assignees: Autogen Research Pty Ltd., North Brighton, Victoria (AU); Deakin Univer (57) ABSTRACT sity, Waurn Ponds, Victoria (AU) The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and (21) Appl. No.: 10/545,099 metabolic energy levels in animals including humans. More (22) PCT Fed: Feb. 10, 2004 particularly, the present invention provides a ligand of the protein, Beacon, and its homologs. The identification of a (86) PCT No.: PCT/AUO4/OO147 Beacon ligand permits the identification of agents which agonize or antagonize the Beacon-ligand interaction and, S 371(c)(1), hence, the development of therapeutic molecules useful in (2), (4) Date: May 4, 2006 modulating obesity, diabetes and/or energy imbalance. Patent Application Publication Jun. 14, 2007 Sheet 1 of 5 US 2007/0135335 A1 ?º?uOIO VIºInáH Patent Application Publication Jun. 14, 2007 Sheet 2 of 5 US 2007/0135335 A1 (II9.InáÃC)Iaun????9.InáH Patent Application Publication Jun. 14, 2007 Sheet 3 of 5 US 2007/0135335 A1 Patent Application Publication Jun. 14, 2007 Sheet 4 of 5 US 2007/0135335 A1 2 O 50 100 150 200 250 300 i Time (s) Figure 3A S. 800 2. 700 600 500 400 30 2 200 3 100 4. () O O 100 200 300 400 500 600 700 (s) Figure 3B O 5 100 150 200 250 300 (s) Figure 3C Patent Application Publication Jun. 14, 2007 Sheet 5 of 5 US 2007/0135335 A1 SO 100 150 200 250 300 (s) Figure 3D O 100 200 300 400 500 (s) Figure 3E O 120 240 360 480 600 (s) Figure 3F US 2007/01 35335 A1 Jun. 14, 2007 THERAPEUTIC MOLECULES 0008. In Australia, the recent AusLiab study estimated that 7.5 million Australians (60%) aged 25 years and over BACKGROUND OF THE INVENTION were overweight or obese. Of these, 2.6 million (21%) were 0001) 1. Field of the Invention obese (BMI>30) (Dunstan et al., Diabetes Res. Clin. Pract. 0002 The present invention relates generally to a ligand 57: 119-129, 2002). Similarly, the prevalence of obesity in for a protein associated with or which acts as a marker for the U.S. increased substantially between 1991 and 1998, conditions of inter alia a healthy or unhealthy state, includ increasing from 12% to 18% in Americans during this period ing the presence or absence of a disorder associated with (Mokdad et al., JAMA 282(16): 1519-1522, 1999). myopathy, obesity, anorexia, weight maintenance, diabetes, 0009. The high and increasing prevalence of obesity has disorders associated with mitochondrial dysfunction, serious health implications for both individuals and society genetic disorders, cancer, heart disease, inflammation, dis as a whole. Obesity is a complex and heterogeneous disorder orders associated with the immune system, infertility, dis and has been identified as a key risk indicator of preventable ease associated with the brain and/or metabolic energy morbidity and mortality. Obesity, for example, increases the levels. More particularly, the present invention is directed to risk of a number of other metabolic conditions including a ligand of the protein Beacon and its use or the interaction Type 2 diabetes mellitus and cardiovascular disease (Must et itself in therapeutic and diagnostic protocols for conditions al., JAMA 282(16): 1523-1529, 1999: Kopelman, Nature Such as inter alia a disorder associated with myopathy, 404: 635-643, 2000). Alongside obesity the prevalence of obesity, anorexia, weight maintenance, diabetes, disorders diabetes continues to increase rapidly. The AusLiab survey associated with mitochondrial dysfunction, genetic disor estimated that close to 1 million Australians aged 25 years ders, cancer, heart disease, inflammation, disorders associ and over have Type 2 diabetes (Dunstan et al., 2002 supra). ated with the immune system, infertility, disease associated This represents approximately 7.5% of the population. In the with the brain and/or metabolic energy levels. The Beacon U.S., the number of adults with diabetes increased by 49% ligand interaction is further useful as a target for the design between 1991 and 2000 (Marx, Science 686-689, 2002). It and/or identification of modulators of the activity and/or has been estimated that about 17 million people in the U.S. function of Beacon, its ligand or its interaction. The Subject have Type 2 diabetes and an equal number are thought to be ligand, therefore, is useful as a drug target or a target for pre-diabetic (Marx, 2002 supra). In Australia, the annual drug design or development. costs of obesity associated with diabetes and other disease 0003 2. Description of the Prior Art conditions has been conservatively estimated to be AUS S810 million for 1992-93 (National Health and Medical 0004 Bibliographic details of references provided in the Research Council, Acting on Australia's weight: A Strategy Subject specification are listed at the end of the specification. for the prevention of overweight and obesity. Canberra. 0005 Reference to any prior art in this specification is National Health and Medical Research Council, 1996). The not, and should not be taken as, an acknowledgment or any direct costs of diabetes and its complications in Australia in form of Suggestion that this prior art forms part of the 1993-94 were estimated at S681 million, or 2.2% of total common general knowledge in any country. health system costs in that year (Australian Institute of 0006 The increasing sophistication of recombinant DNA Health and Welfare (AIWH), Australia's Health, 2002, Can technology is greatly facilitating research and development berra: AIWH). in the medical, veterinary and allied human and animal 0010. A genetic basis for the etiology of obesity is health fields. This is particularly the case in the investigation indicated inter alia from Studies in twins, adoption studies of the genetic bases involved in the etiology of certain and population-based analyses which suggest that genetic disease conditions. One particularly significant condition effects account for 25-80% of the variation in body weight from the stand point of morbidity and mortality is obesity in the general population (Bouchard, 1994, Supra; Kopelman and its association with Type 2 diabetes and cardiovascular et al., Int. J. Obesity 18: 188-191, 1994; Ravussin, Metabo disease. lism 44(3): 12-14, 1995). It is considered that genes deter 0007 Obesity is defined as a pathological excess of body mine the possible range of body weight in an individual and fat and is the result of an imbalance between energy intake then the environment influences the point within this range and energy expenditure for a Sustained period of time. where the individual is located at any given time (Bouchard, Obesity is the most common metabolic disease found in 1994, Supra). However, despite numerous studies into genes affluent societies. The prevalence of obesity in these affluent thought to be involved in the pathogenesis of obesity, there Societies is alarmingly high, ranging from 10% to upwards have been Surprisingly few significant findings in this area. of 50% in some sub-populations (Bouchard, The genetics of In addition, genome-wide scans in various population Obesity, Boca Raton: CRC Press, 1994). Of particular groups have not produced definitive evidence of the chro concern is the fact that the prevalence of obesity appears to mosomal regions having a major effect on obesity. be rising consistently in affluent Societies and is now 0011) A number of tissues have been implicated in the increasing rapidly in less prosperous nations as they become pathophysiology of obesity and type 2 diabetes, and of more affluent and/or adopt cultural practices similar to those particular interest is the hypothalamus. The hypothalamus in more affluent countries (Zimmet, Diabetes Care 15: has long been recognized as a key brain area in the regula 232-252, 1992). The escalating rates of obesity globally tion of energy intake (Stellar, Psychol Rev 61: 5-22, 1954) have resulted in the World Health Organisation declaring an and it is now widely accepted that the hypothalamus plays obesity epidemic worldwide (World Trade Organisation. a central role in energy homeostasis, integrating and coor Obesity. Preventing and managing the global epidemic. dinating a large number of factors produced by and/or acting Report of a WHO Consultation on Obesity. Geneva: World on the hypothalamus. A number of these factors have been Health Organisation, 1998). investigated for their role in energy balance and body weight US 2007/01 35335 A1 Jun. 14, 2007 regulation, including neuropeptide Y, corticotropin-releas Diabetes 49: 1766-1771, 2000). Beacon treated animals ing hormone, melanin-concentrating hormone, leptin and revealed that the increase in body weight was a direct insulin. It has been proposed that genetic alterations per consequence of increased food intake as the treatment turbing the metabolic pathways regulating energy balance in affected neither the physical activity nor the energy expen the hypothalamus could contribute to the development of diture. The increase in body weight corresponded largely to obesity, and Subsequently diabetes. Thus, an important step an increase in fat content as the weight of the other organs in understanding the function of the hypothalamus in regu remained unchanged (Walder et al., Int.
Recommended publications
  • Association of Congenital Diaphragmatic Hernia and Hiatal Hernia with Tetrasomy 18P

    Association of Congenital Diaphragmatic Hernia and Hiatal Hernia with Tetrasomy 18P

    Accepted Manuscript Association of Congenital Diaphragmatic Hernia and Hiatal Hernia with Tetrasomy 18p Jamir Arlikar , MD Victor McKay , MD Paul Danielson , MD PII: S2213-5766(14)00068-2 DOI: 10.1016/j.epsc.2014.05.006 Reference: EPSC 221 To appear in: Journal of Pediatric Surgery Case Reports Received Date: 25 March 2014 Revised Date: 7 May 2014 Accepted Date: 17 May 2014 Please cite this article as: Arlikar J, McKay V, Danielson P, Association of Congenital Diaphragmatic Hernia and Hiatal Hernia with Tetrasomy 18p, Journal of Pediatric Surgery Case Reports (2014), doi: 10.1016/j.epsc.2014.05.006. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT ASSOCIATION OF CONGENITAL DIAPHRAGMATIC HERNIA AND HIATAL HERNIA WITH TETRASOMY 18P Running title: “CDH and Hiatal Hernia with Tetrasomy 18p” Jamir Arlikar, MD*, Victor McKay, MD**, and Paul Danielson, MD* Division of Pediatric Surgery* and Division of Neonatology** All Children’s Hospital Johns Hopkins Medicine St. Petersburg, FL MANUSCRIPT Corresponding Author: Paul Danielson, MD All Children’s Hospital Johns Hopkins Medicine 601 Fifth Street South, Dept 70-6600 St. Petersburg, FL 33701 ACCEPTED Tel: 727-767-4109 Fax: 727-767-4346 Email: [email protected] 1 ACCEPTED MANUSCRIPT Abstract: We report a case of a newborn with tetrasomy 18p who presents with both a congenital diaphragmatic hernia and a giant hiatal hernia.
  • Newborn Screening for X-Linked Adrenoleukodystrophy: Information for Parents

    Newborn Screening for X-Linked Adrenoleukodystrophy: Information for Parents

    Newborn Screening for X-linked Adrenoleukodystrophy: Information for Parents Baby girl with ABCD1 gene mutation What is newborn screening? the symptoms of ALD during childhood. Rarely, some women who are carriers of ALD develop mild symptoms as adults. It Newborn screening involves laboratory testing on a small is important for your family to meet with a genetic counselor sample of blood collected from newborns’ heels. Every state to talk about the genetics of ALD and implications for other has a newborn screening program to identify infants with rare family members. disorders, which would not usually be detected at birth. Early diagnosis and treatment of these disorders often prevents Why do only boys have ALD? serious complications. Only boys have ALD because it is caused by a mutation in What is adrenoleukodystrophy (ALD)? a gene (ABCD1) on the X chromosome, called “X-linked inheritance.” Males only have one X chromosome so they have ALD is one of over 40 disorders included in newborn screening one ABCD1 gene. Males with a nonfunctioning ABCD1 gene in New York State. It is a rare genetic disorder. People with have ALD. Females have 2 X chromosomes, so they have two ALD are unable to breakdown a component of food called ABCD1 genes. Females with one ABCD1 gene mutation will very long chain fatty acids (VLCFA). If VLCFA are not broken be carriers. When a mother is a carrier of ALD, each son has a down, they build up in the body and cause symptoms. 50% chance of inheriting the disorder and each daughter has a 50% chance of being a carrier.
  • First Case Report of Maternal Mosaic Tetrasomy 9P Incidentally Detected on Non-Invasive Prenatal Testing

    First Case Report of Maternal Mosaic Tetrasomy 9P Incidentally Detected on Non-Invasive Prenatal Testing

    G C A T T A C G G C A T genes Article First Case Report of Maternal Mosaic Tetrasomy 9p Incidentally Detected on Non-Invasive Prenatal Testing Wendy Shu 1,*, Shirley S. W. Cheng 2 , Shuwen Xue 3, Lin Wai Chan 1, Sung Inda Soong 4, Anita Sik Yau Kan 5 , Sunny Wai Hung Cheung 6 and Kwong Wai Choy 3,* 1 Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China; [email protected] 2 Clinical Genetic Service, Hong Hong Children Hospital, Ngau Tau Kok, Hong Kong, China; [email protected] 3 Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Hong Kong, China; [email protected] 4 Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China; [email protected] 5 Prenatal Diagnostic Laboratory, Tsan Yuk Hospital, Sai Ying Pun, Hong Kong, China; [email protected] 6 NIPT Department, NGS Lab, Xcelom Limited, Hong Kong, China; [email protected] * Correspondence: [email protected] (W.S.); [email protected] (K.W.C.); Tel.: +852-25-957-359 (W.S.); +852-35-053-099 (K.W.C.) Abstract: Tetrasomy 9p (ORPHA:3390) is a rare syndrome, hallmarked by growth retardation; psychomotor delay; mild to moderate intellectual disability; and a spectrum of skeletal, cardiac, renal and urogenital defects. Here we present a Chinese female with good past health who conceived her pregnancy naturally. Non-invasive prenatal testing (NIPT) showed multiple chromosomal aberrations were consistently detected in two sampling times, which included elevation in DNA from Citation: Shu, W.; Cheng, S.S.W.; chromosome 9p.
  • Sema4 Noninvasive Prenatal Select

    Sema4 Noninvasive Prenatal Select

    Sema4 Noninvasive Prenatal Select Noninvasive prenatal testing with targeted genome counting 2 Autosomal trisomies 5 Trisomy 21 (Down syndrome) 6 Trisomy 18 (Edwards syndrome) 7 Trisomy 13 (Patau syndrome) 8 Trisomy 16 9 Trisomy 22 9 Trisomy 15 10 Sex chromosome aneuploidies 12 Monosomy X (Turner syndrome) 13 XXX (Trisomy X) 14 XXY (Klinefelter syndrome) 14 XYY 15 Microdeletions 17 22q11.2 deletion 18 1p36 deletion 20 4p16 deletion (Wolf-Hirschhorn syndrome) 20 5p15 deletion (Cri-du-chat syndrome) 22 15q11.2-q13 deletion (Angelman syndrome) 22 15q11.2-q13 deletion (Prader-Willi syndrome) 24 11q23 deletion (Jacobsen Syndrome) 25 8q24 deletion (Langer-Giedion syndrome) 26 Turnaround time 27 Specimen and shipping requirements 27 2 Noninvasive prenatal testing with targeted genome counting Sema4’s Noninvasive Prenatal Testing (NIPT)- Targeted Genome Counting analyzes genetic information of cell-free DNA (cfDNA) through a simple maternal blood draw to determine the risk for common aneuploidies, sex chromosomal abnormalities, and microdeletions, in addition to fetal gender, as early as nine weeks gestation. The test uses paired-end next-generation sequencing technology to provide higher depth across targeted regions. It also uses a laboratory-specific statistical model to help reduce false positive and false negative rates. The test can be offered to all women with singleton, twins and triplet pregnancies, including egg donor. The conditions offered are shown in below tables. For multiple gestation pregnancies, screening of three conditions
  • Acute Myeloid Leukemia in Association with Trisomy 22

    Acute Myeloid Leukemia in Association with Trisomy 22

    iMedPub Journals ARCHIVES OF MEDICINE 2015 http://wwwimedpub.com Vol. 7 No. 5:9 De Novo Inversion (16) Acute Al-Ola Abdallah1, Meghana Bansal1, Myeloid Leukemia in Association Steven A Schichman2,3, with Trisomy 22, Deletion 7q Zhifu Xiang1,4 And FLT3 (ITD) Associated with 1 Division of Hematology and Oncology, Complete Remission Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA 2 Department of Pathology, University of Arkansas for Medical Sciences, Little Clinical practice points Rock, Arkansas, USA 3 Pathology and Laboratory Medicine Acute myeloid leukemia (AML) is a heterogeneous neoplastic disorder Service, Central Arkansas Veterans characterized by the accumulation of immature myeloid blasts in the bone marrow. Healthcare System, Little Rock, Arkansas, More than 90% of the patients with inv (16)/t (16;16) AML harbor secondary USA chromosome aberrations and mutations affecting N-RAS, K-RAS, KIT, and FLT3. 4 Division of Hematology and Oncology, Central Arkansas Veterans Healthcare 7q deletions represent a more frequent genetic alteration occurring in System, Little Rock, Arkansas, USA approximately 10% of CBF-AML cases. Our case presents an elderly patient who has de novo AML with inv (16) in association with trisomy 22, del 7 and FLT3 (ITD) mutation; this is a rare Corresponding Author: Dr. Xiang cytogenetic combination. Several factors that indicate an unfavorable prognosis were present in our case; however, our case achieved complete response, possibly reflecting that trisomy 22 Division of Hematology and Oncology, Win- in association with inv (16) is a dominant favorable prognosis regardless of other throp P. Rockefeller Cancer Institute, Univer- sity of Arkansas for Medical Sciences.
  • Mosaic Tetrasomy 9P at Amniocentesis: Prenatal Diagnosis, Molecular Cytogenetic Characterization, and Literature Review

    Mosaic Tetrasomy 9P at Amniocentesis: Prenatal Diagnosis, Molecular Cytogenetic Characterization, and Literature Review

    Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 79e85 Contents lists available at ScienceDirect Taiwanese Journal of Obstetrics & Gynecology journal homepage: www.tjog-online.com Short Communication Mosaic tetrasomy 9p at amniocentesis: Prenatal diagnosis, molecular cytogenetic characterization, and literature review Chih-Ping Chen a,b,c,d,e,f,*, Liang-Kai Wang a, Schu-Rern Chern b, Peih-Shan Wu g, Yu-Ting Chen b, Yu-Ling Kuo h, Wen-Lin Chen a, Meng-Shan Lee a, Wayseen Wang b,i a Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan b Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan c Department of Biotechnology, Asia University, Taichung, Taiwan d School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan e Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwan f Department of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan g Gene Biodesign Co. Ltd, Taipei, Taiwan h Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan i Department of Bioengineering, Tatung University, Taipei, Taiwan article info abstract Article history: Objective: This study was aimed at prenatal diagnosis of mosaic tetrasomy 9p and reviewing the Accepted 17 December 2013 literature. Materials and methods: A 37-year-old woman underwent amniocentesis at 20 weeks’ gestation because Keywords: of advanced maternal age and fetal ascites. Cytogenetic analysis of cultured amniocytes revealed 21.4% amniocentesis (6/28 colonies) mosaicism for a supernumerary i(9p). Repeat amniocentesis was performed at 23 weeks’ mosaicism gestation. Array comparative genomic hybridization, interphase fluorescence in situ hybridization, and supernumerary isochromosome 9p quantitative fluorescent polymerase chain reaction were applied to uncultured amniocytes, and con- tetrasomy 9p ventional cytogenetic analysis was applied to cultured amniocytes.
  • Hereditary Spherocytosis: Clinical Features

    Hereditary Spherocytosis: Clinical Features

    Title Overview: Hereditary Hematological Disorders of red cell shape. Disorders Red cell Enzyme disorders Disorders of Hemoglobin Inherited bleeding disorders- platelet disorders, coagulation factor Anthea Greenway MBBS FRACP FRCPA Visiting Associate deficiencies Division of Pediatric Hematology-Oncology Duke University Health Service Inherited Thrombophilia Hereditary Disorders of red cell Disorders of red cell shape (cytoskeleton): cytoskeleton: • Mutations of 5 proteins connect cytoskeleton of red cell to red cell membrane • Hereditary Spherocytosis- sphere – Spectrin (composed of alpha, beta heterodimers) –Ankyrin • Hereditary Elliptocytosis-ellipse, elongated forms – Pallidin (band 4.2) – Band 4.1 (protein 4.1) • Hereditary Pyropoikilocytosis-bizarre red cell forms – Band 3 protein (the anion exchanger, AE1) – RhAG (the Rh-associated glycoprotein) Normal red blood cell- discoid, with membrane flexibility Hereditary Spherocytosis: Clinical features: • Most common hereditary hemolytic disorder (red cell • Neonatal jaundice- severe (phototherapy), +/- anaemia membrane) • Hemolytic anemia- moderate in 60-75% cases • Mutations of one of 5 genes (chromosome 8) for • Severe hemolytic anaemia in 5% (AR, parents ASx) cytoskeletal proteins, overall effect is spectrin • fatigue, jaundice, dark urine deficiency, severity dependant on spectrin deficiency • SplenomegalSplenomegaly • 200-300:million births, most common in Northern • Chronic complications- growth impairment, gallstones European countries • Often follows clinical course of affected
  • Emergencies in the Treatment of Wandering Spleen Osher Cohen MD1, Arthur Baazov MD1, Inbal Samuk MD1, Michael Schwarz MD2, Dragan Kravarusic MD1 and Enrique Freud MD1

    Emergencies in the Treatment of Wandering Spleen Osher Cohen MD1, Arthur Baazov MD1, Inbal Samuk MD1, Michael Schwarz MD2, Dragan Kravarusic MD1 and Enrique Freud MD1

    ORIGINAL ARTICLES ,0$-ǯ92/20ǯ-81(2018 Emergencies in the Treatment of Wandering Spleen Osher Cohen MD1, Arthur Baazov MD1, Inbal Samuk MD1, Michael Schwarz MD2, Dragan Kravarusic MD1 and Enrique Freud MD1 1Departments of Pediatric and Adolescent Surgery and 2Pediatric Radiology, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel and nonspecific clinical presentation [2], making diagnosis ABSTRACT: Background: Wandering spleen is a rare entity that may pose difficult and the potential for a delayed diagnosis high [3]. a surgical emergency following torsion of the splenic vessels, Torsion of the splenic vessels has been described in 64% mainly because of a delayed diagnosis. Complications after of children with wandering spleen [4,5]. The splenic veins surgery for wandering spleen may necessitate emergency are the first vessels compromised because of their lower pres- treatment. sure [6], causing splenic engorgement and capsule stretching. Objectives: To describe the clinical course and treatment for Accordingly, abdominal pain, which can be acute, recurrent, children who underwent emergency surgeries for wandering or chronic, is the most common clinical presentation [7]. spleen at a tertiary pediatric medical center over a 21 year Progression of the torsion may lead to ischemic injury to the period and to indicate the pitfalls in diagnosis and treatment spleen and ultimately splenic necrosis [1]. as reflected by our experience and in the literature. Surgery is considered the only safe treatment for wander- Methods: The database of a tertiary pediatric medical center ing spleen [8], although there are a few reports on the use of was searched retrospectively for all children who underwent conservative methods [9].
  • MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002

    MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002

    MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002 Michigan Department of Community Health Community Public Health Agency and Center for Health Statistics 3423 N. Martin Luther King Jr. Blvd. P. O. Box 30691 Lansing, Michigan 48909 Michigan Department of Community Health James K. Haveman, Jr., Director B-274a (March, 2002) Authority: P.A. 236 of 1988 BIRTH DEFECTS REGISTRY MICHIGAN DEPARTMENT OF COMMUNITY HEALTH BIRTH DEFECTS REGISTRY STAFF The Michigan Birth Defects Registry staff prepared this manual to provide the information needed to submit reports. The manual contains copies of the legislation mandating the Registry, the Rules for reporting birth defects, information about reportable and non reportable birth defects, and methods of reporting. Changes in the manual will be sent to each hospital contact to assist in complete and accurate reporting. We are interested in your comments about the manual and any suggestions about information you would like to receive. The Michigan Birth Defects Registry is located in the Office of the State Registrar and Division of Health Statistics. Registry staff can be reached at the following address: Michigan Birth Defects Registry 3423 N. Martin Luther King Jr. Blvd. P.O. Box 30691 Lansing MI 48909 Telephone number (517) 335-8678 FAX (517) 335-9513 FOR ASSISTANCE WITH SPECIFIC QUESTIONS PLEASE CONTACT Glenn E. Copeland (517) 335-8677 Cytogenetics Laboratory Reporting Instructions I. INTRODUCTION This manual provides detailed instructions on the proper reporting of diagnosed birth defects by cytogenetics laboratories. A report is required from cytogenetics laboratories whenever a reportable condition is diagnosed for patients under the age of two years.
  • Wandering Spleen with Torsion Causing Pancreatic Volvulus and Associated Intrathoracic Gastric Volvulus: an Unusual Triad and Cause of Acute Abdominal Pain

    Wandering Spleen with Torsion Causing Pancreatic Volvulus and Associated Intrathoracic Gastric Volvulus: an Unusual Triad and Cause of Acute Abdominal Pain

    JOP. J Pancreas (Online) 2015 Jan 31; 16(1):78-80. CASE REPORT Wandering Spleen with Torsion Causing Pancreatic Volvulus and Associated Intrathoracic Gastric Volvulus: An Unusual Triad and Cause of Acute Abdominal Pain Yashant Aswani, Karan Manoj Anandpara, Priya Hira Departments of Radiology Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India , ABSTRACT Context Wandering spleen is a rare medical entity in which the spleen is orphaned of its usual peritoneal attachments and thus assumes an ever wandering and hypermobile state. This laxity of attachments may even cause torsion of the splenic pedicle. Both gastric volvulus and wandering spleen share a common embryology owing to mal development of the dorsal mesentery. Gastric volvulus complicating a wandering spleen is, however, an extremely unusual association, with a few cases described in literature. Case Report We report a case of a young female who presented with acute abdominal pain and vomiting. Radiological imaging revealed an intrathoracic gastric. Conclusionvolvulus, torsion in an ectopic spleen, and additionally demonstrated a pancreatic volvulus - an unusual triad, reported only once, causing an acute abdomen. The patient subsequently underwent an emergency surgical laparotomy with splenopexy and gastropexy Imaging is a must for definitive diagnosis of wandering spleen and the associated pathologic conditions. Besides, a prompt surgicalINTRODUCTION management circumvents inadvertent outcomes. Laboratory investigations showed the patient to be Wandering spleen, a medical enigma, is a rarity. Even though gastric volvulus and wandering spleen share a anaemic (Hb 9 gm %) with leucocytosis (16,000/cubic common embryological basis; cases of such an mm) and a predominance of polymorphonuclear cells association have rarely been described.
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
  • Orphanet Report Series Rare Diseases Collection

    Orphanet Report Series Rare Diseases Collection

    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic